GE HealthCare Technologies (GEHC) just secured FDA 510(k) clearance for View, its cloud-native diagnostic viewer within the Genesis Radiology Workspace. This regulatory milestone could influence how investors think about the stock.

Despite the FDA clearance for View and a steady stream of product news and conference appearances in early March, GE HealthCare’s share price has been under pressure, with a 30 day share price return of 9.82% and a 1 year total shareholder return of 14.87%. Overall, recent trading suggests momentum has been fading rather than building.

If this kind of health tech news has your attention, it could be a good moment to look at other opportunities in the space through our 32 healthcare AI stocks.

With GE HealthCare’s shares showing a 30 day return of 9.82% and a 1 year total return of 14.87%, alongside FDA progress and new products, is the current price still attractive or is the market already pricing in future growth?

Most Popular Narrative: 22% Undervalued

At a last close of $72.73 versus a narrative fair value of $93.25, GE HealthCare is framed as undervalued, with that gap hinging on how future earnings and margins play out.

The pipeline of new high-impact products, like Radiopharmaceuticals, Total Body PET, and Photon Counting CT, is anticipated to drive future revenue growth and potentially improve margins.

Curious what kind of revenue path and margin profile could justify that higher fair value, and how long it might take to play out? The most followed narrative leans on detailed product roll out assumptions, recurring digital revenue, and a future earnings multiple that is not out of line with larger medtech peers. If you want to see which specific growth and profitability numbers sit behind that $93.25 figure, the full story is worth a read.

Result: Fair Value of $93.25 (UNDERVALUED)

However, there are still clear pressure points, including tariff and China regulatory risks and weaker free cash flow, that could challenge those earnings and valuation assumptions.

Next Steps

With both upside potential and real risks on the table, do you want to see the full picture and move quickly on your own view by checking the 5 key rewards and 1 important warning sign?

Looking for more investment ideas?

If you stop with one company, you risk missing opportunities that better fit your goals, so use the Simply Wall Street Screener to widen your watchlist confidently.

• Spot potential value by scanning our 48 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their underlying businesses.
• Prioritise strength by checking companies in the solid balance sheet and fundamentals stocks screener (41 results) that focus on healthier finances and lower debt profiles.
• Target steady income by reviewing our 14 dividend fortresses that focus on higher yielding businesses many income focused investors keep on their radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.